New Modifications to Vancomycin Show Promise in Combating Antibiotic Resistance

Scientists at the The Scripps Research Institute (TSRI) in the United States have modified an existing antibiotic, vancomycin, to to be more potent and less likely to drive the development of resistance than its original predecessor.

Researchers made changes to the original molecule to (1) overcome the weaknesses that have allowed bacteria to resist its effects, and (2) add two new mechanisms by which the drug can kill the bacteria. The modified drug was able to kill samples of vancomycin-resistant enterococci (VRE) in the lab and retained nearly full potency after 50 rounds of exposure to the bacterium. Although this modified antibiotic has yet to be tested in humans or animals, it shows great promise in its ability to combat drug-resistant infections and resist the development of resistance.

To read more on this story from the BBC, please click here.



The British Society for Antimicrobial Chemotherapy (BSAC)
© 2020 Registered Charity 1093118.

Registered as a company limited by guarantee in England & Wales No: 4443910

By using this site, you agree to using cookies.
For more details about cookies and how to disable them, see resource here
Privacy Policy